Technical Analysis for GOVX - GeoVax Labs, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Calm After Storm | Range Contraction | -3.74% | |
Wide Bands | Range Expansion | -3.74% | |
Up 3 Days in a Row | Strength | -3.74% | |
Up 4 Days in a Row | Strength | -3.74% | |
Calm After Storm | Range Contraction | -2.17% | |
Inside Day | Range Contraction | -2.17% | |
Wide Bands | Range Expansion | -2.17% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 5% | about 2 hours ago |
Possible NR7 | about 4 hours ago |
Fell Below Previous Day's Low | about 6 hours ago |
60 Minute Opening Range Breakdown | about 6 hours ago |
Down 3% | about 6 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 03/07/2023
GeoVax Labs, Inc. Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally. It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Clinical Medicine Infectious Diseases Immunotherapies Vaccines Allergy Hepatitis B Viruses Department Of Defense HIV Immunodeficiency Virus Fever U.S. Department Of Defense Virology Malaria Ebola Scripps Zika Chronic Hepatitis Hiv Vaccine Vaccinia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.3 |
52 Week Low | 0.1 |
Average Volume | 2,134,493 |
200-Day Moving Average | 1.14 |
50-Day Moving Average | 0.72 |
20-Day Moving Average | 0.81 |
10-Day Moving Average | 0.86 |
Average True Range | 0.12 |
RSI | 56.33 |
ADX | 48.21 |
+DI | 37.63 |
-DI | 7.85 |
Chandelier Exit (Long, 3 ATRs) | 1.03 |
Chandelier Exit (Short, 3 ATRs) | 0.96 |
Upper Bollinger Bands | 1.02 |
Lower Bollinger Band | 0.60 |
Percent B (%b) | 0.72 |
BandWidth | 52.43 |
MACD Line | 0.05 |
MACD Signal Line | 0.04 |
MACD Histogram | 0.0128 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.98 | ||||
Resistance 3 (R3) | 0.98 | 0.95 | 0.96 | ||
Resistance 2 (R2) | 0.95 | 0.93 | 0.95 | 0.96 | |
Resistance 1 (R1) | 0.93 | 0.92 | 0.92 | 0.93 | 0.95 |
Pivot Point | 0.90 | 0.90 | 0.90 | 0.90 | 0.90 |
Support 1 (S1) | 0.88 | 0.88 | 0.87 | 0.88 | 0.85 |
Support 2 (S2) | 0.85 | 0.87 | 0.85 | 0.84 | |
Support 3 (S3) | 0.83 | 0.85 | 0.84 | ||
Support 4 (S4) | 0.83 |